• Avinger Inc (NASDAQ: AVGR) has announced that clinical data from the INSIGHT study were presented at the VIVA (Vascular InterVentional Advances) conference.

• The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for in-stent restenosis (ISR) in lower extremity arteries.

• Related: Avinger Files US Application For New Pantheris In-Stent Restenosis Indication.

• Key outcomes presented from the trial include:

  • 82% luminal gain (increase in the channel for blood flow) following the procedure.

  • 93% freedom from target lesion restenosis at six months post-procedure.

  • 89% freedom from target lesion restenosis at 12 months post-procedure.

  • No amputations for the six or 12-month cohorts of patients.

  • 0.96 mean ankle-brachial index at six months from a baseline of 0.69 pre-procedure. 71% improvement in Rutherford Class (a measure of disease severity) at six months.

• Price Action: AVGR stock is up 14.1% at $0.79 during the market session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Pfizer, BioNTech Seek Approval For COVID-19 Vaccine In Kids Aged 5-11: Reuters

• After Sweden, Denmark Now Finland Stops Use of Moderna COVID-19 Jab In Young People: Report

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.